Billottet Clotilde, Quemener Cathy, Bikfalvi Andreas
INSERM U1029, Talence, France; Université Bordeaux I, Talence, France.
Biochim Biophys Acta. 2013 Dec;1836(2):287-95. doi: 10.1016/j.bbcan.2013.08.002. Epub 2013 Aug 27.
CXC chemokines are involved in chemotaxis, regulation of cell growth, induction of apoptosis and modulation of angiostatic effects. CXCL9, CXCL10, CXCL11, CXCL4 and its variant CXCL4L1 are members of the CXC chemokine family, which bind to the CXCR3 receptor to exert their biological effects. These chemokines are associated with a variety of human diseases including chronic inflammation, immune dysfunction, cancer and metastasis. In this review, we focus on accumulating evidence demonstrating the pivotal role of CXCR3 in tumor progression. Its effects are mediated directly in tumor cells or indirectly through the regulation of angiogenesis and tumor immunity. Understanding the emerging role of CXCR3 and its signaling mechanisms further validates this receptor as a biomarker and therapeutic target for tumor progression and tumor angiogenesis.
CXC趋化因子参与趋化作用、细胞生长调节、细胞凋亡诱导及血管生成抑制效应的调节。CXCL9、CXCL10、CXCL11、CXCL4及其变体CXCL4L1是CXC趋化因子家族的成员,它们与CXCR3受体结合以发挥其生物学效应。这些趋化因子与多种人类疾病相关,包括慢性炎症、免疫功能障碍、癌症和转移。在本综述中,我们着重于积累的证据,这些证据证明了CXCR3在肿瘤进展中的关键作用。其作用直接在肿瘤细胞中介导,或通过血管生成和肿瘤免疫的调节间接介导。了解CXCR3的新作用及其信号传导机制进一步证实了该受体作为肿瘤进展和肿瘤血管生成的生物标志物和治疗靶点。